Analyst Ratings For Eyegate Pharmaceuticals (NASDAQ:EYEG)
Today, HC Wainwright reiterated its Buy rating on Eyegate Pharmaceuticals (NASDAQ:EYEG) with a price target of $3.00.
Some recent analyst ratings include
- 2/6/2018-HC Wainwright Reiterated Rating of Buy .
- 5/19/2017-Noble Financial Reiterated Rating of Buy.
- 12/6/2016-Chardan Capital Reiterated Rating of Buy.
- 12/1/2016-Rodman & Renshaw Reiterated Rating of Buy.
- 6/28/2016-Maxim Group Reiterated Rating of Hold.
Recent Insider Trading Activity For Eyegate Pharmaceuticals (NASDAQ:EYEG)
Eyegate Pharmaceuticals (NASDAQ:EYEG) has insider ownership of 24.60% and institutional ownership of 11.94%.
- On 8/15/2017 Sarah Romano, CFO, bought 10,000 with an average share price of $1.00 per share and the total transaction amounting to $10,000.00.
- On 8/10/2017 Stephen From, Insider, bought 12,500 with an average share price of $1.03 per share and the total transaction amounting to $12,875.00.
- On 3/6/2017 Morton Goldberg, Director, sold 8,919 with an average share price of $3.00 per share and the total transaction amounting to $26,757.00.
- On 9/15/2016 Stephen From, Insider, bought 15,000 with an average share price of $1.49 per share and the total transaction amounting to $22,350.00.
- On 6/15/2016 Morton Goldberg, Director, sold 15,000 with an average share price of $3.16 per share and the total transaction amounting to $47,400.00.
- On 6/10/2016 Ventech Capital Ii, Major Shareholder, sold 28,600 with an average share price of $3.04 per share and the total transaction amounting to $86,944.00.
- On 6/8/2016 Ventech Capital Ii, Major Shareholder, sold 29,400 with an average share price of $3.25 per share and the total transaction amounting to $95,550.00.
Recent Trading Activity for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Shares of Eyegate Pharmaceuticals closed the previous trading session at 0.61 up +0.01 1.41% with 144041 shares trading hands.
